We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Ruby Tuesday Jumps 20% After Company Explores Sale or Merger
Shares of Ruby Tuesday, Inc. surged almost 20% late Monday after the restaurant chain said it will explore strategic alternatives including a sale or merger to keep it in business.
The company reported preliminary results for the third quarter ended Feb. 28. Sales of established locations were down 4%. This is considered a key metric for financial health because it strips out the volatility of newly opened and closed locations, according to the Associate Press.
“We believe now is the right time to explore strategic alternatives that have the potential to position the business for long-tern success and to carry that legacy forward,” said Stephen Sadove, Non-Executive Chairman, in the press release.
The restaurant chain is in the beginning stage of strategic and financial review and doesn’t plan on making any further public comment until it has been completed. No assurance was given to the outcome and timing.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>